Survival does not differ significantly between patients receiving pentostatin as initial induction, compared with those crossed over from interferon therapy.

P = .59. Figure shows estimated distributions of overall survival (Kaplan-Meier estimates) from date of registration for pentostatin therapy, by phase of treatment. Tick marks indicate patients who were alive at last contact.